Nomenclature
Short Name:
NIM1
Full Name:
Serine/threonine-protein kinase NIM1
Alias:
- EC 2.7.11.1
- MGC42105
Classification
Type:
Protein-serine/threonine kinase
Group:
CAMK
Family:
CAMKL
SubFamily:
NIM1
Structure
Mol. Mass (Da):
49,606
# Amino Acids:
436
# mRNA Isoforms:
1
mRNA Isoforms:
49,606 Da (436 AA; Q8IY84)
4D Structure:
NA
1D Structure:
Subfamily Alignment
Domain Distribution:
| Start | End | Domain |
|---|---|---|
| 74 | 325 | Pkinase |
Distribution
Based on gene microarray analysis from the NCBI
Human Tissue Distribution
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
% Max Expression:
Mean Expression:
Number of Samples:
Standard Deviation:
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Evolution
Species Conservation
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
PhosphoNET % Identity:
PhosphoNET % Similarity:
Homologene %
Identity:
100
100
100
99.5
99.7
99.5
98.6
98.6
99
-
-
94
-
-
-
93.5
97.2
94
-
-
-
91.7
96.5
92
91.7
95.8
92
-
-
-
46.3
51.8
-
77.9
87.8
78
-
-
76
69.8
82.6
71
-
-
-
-
-
53
-
-
-
39.1
56.6
47
56
68.8
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
For a wider analysis go to PhosphoNET Evolution in PhosphoNET
Regulation
Activation:
Activated by phosphorylation at Thr-229, probably by autophosphorylation.
Inhibition:
NA
Synthesis:
NA
Degradation:
NA
Protein Kinase Specificity
Matrix of observed frequency (%) of amino acids in aligned protein substrate phosphosites
Matrix Type:
Predicted from the application of the Kinexus Kinase Substrate Predictor Version 2.0 algorithm, which was trained with over 10,000 kinase-protein substrate pairs and 8,000 kinase-peptide substrate pairs.
Domain #:
1
Inhibitors
For further details on these inhibitors click on the Compound Name and enter it into DrugKiNET or click on the ID's
Based on in vitro and/or in vivo phosphorylation data
| Compound Name | KD, Ki or IC50 (nM) | PubChem ID | ChEMBL ID | PubMed ID |
|---|
| Staurosporine | Kd = 140 nM | 5279 | 22037378 | |
| R406 | Kd = 660 nM | 11984591 | 22037378 | |
| BI2536 | Kd = 770 nM | 11364421 | 513909 | 22037378 |
| Dovitinib | Kd = 850 nM | 57336746 | 22037378 | |
| Sunitinib | Kd = 850 nM | 5329102 | 535 | 19654408 |
| WZ3146 | Kd > 1 µM | 44607360 | 20033049 | |
| WZ4002 | Kd > 1 µM | 44607530 | 20033049 | |
| KW2449 | Kd = 1.1 µM | 11427553 | 1908397 | 22037378 |
| SU14813 | Kd = 1.1 µM | 10138259 | 1721885 | 22037378 |
| Bosutinib | Kd = 1.5 µM | 5328940 | 288441 | 22037378 |
| Lestaurtinib | Kd = 1.8 µM | 126565 | 22037378 | |
| NVP-TAE684 | Kd = 2.6 µM | 16038120 | 509032 | 22037378 |
| TG101348 | Kd = 4.4 µM | 16722836 | 1287853 | 22037378 |
| Crizotinib | Kd = 4.6 µM | 11626560 | 601719 | 22037378 |
Disease Linkage
Mutagenesis Experiments:
Insertional mutagenesis studies in mice have not yet revealed a role for this protein kinase in mouse cancer oncogenesis. NIM1 phosphotransferase activity can be inhibited, and autophosphorylation can be induced by a T229A mutation. The NIM1 can be constitutively activated on through a T229E mutation.
Mutation Rate in All Cancers:
Percent mutation rates per 100 amino acids length in human cancers: 0.11 % in 24,782 diverse cancer specimens. This rate is a modest 1.53-fold higher than the average rate of 0.075 % calculated for human protein kinases in general.
Mutation Rate in Specific Cancers:
Highest percent mutation rates per 100 amino acids length in human cancers: 0.66 % in 864 skin cancers tested; 0.65 % in 1270 large intestine cancers tested; 0.31 % in 589 stomach cancers tested; 0.23 % in 603 endometrium cancers tested; 0.21 % in 1634 lung cancers tested; 0.18 % in 127 biliary tract cancers tested; 0.14 % in 833 ovary cancers tested; 0.12 % in 382 soft tissue cancers tested; 0.1 % in 710 oesophagus cancers tested; 0.1 % in 441 autonomic ganglia cancers tested; 0.08 % in 548 urinary tract cancers tested; 0.08 % in 273 cervix cancers tested; 0.05 % in 881 prostate cancers tested; 0.05 % in 1512 liver cancers tested; 0.05 % in 1459 pancreas cancers tested; 0.05 % in 1372 breast cancers tested; 0.04 % in 1276 kidney cancers tested.
Comments:
Only 1 deletion and 1 insertion and no complex mutations are noted on the COSMIC website.